NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
Clinical Trials
11 trialsNCT02087475 2019-06-05
Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT03416517 2019-02-15
Anlotinib and Irinotecan for Ewing Sarcoma
Peking University People's Hospital
Phase 1/2 Unknown
NCT03303495 2017-10-06
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Sun Yat-sen University
Phase 3 Unknown
NCT00433927 2014-03-14
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
Ludwig-Maximilians - University of Munich
Phase 3 Unknown
NCT00408551 2013-12-19
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00513266 2009-08-07
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00509964 2007-08-01
Second-Line Irinotecan vs. ILF for AGC
Gachon University Gil Medical Center
Phase 2 Unknown
NCT00506207 2007-07-25
TIROX
National Cancer Center, Korea
Phase 1 Unknown
NCT00506571 2007-07-25
TIROX2
National Cancer Center, Korea
Phase 2 Unknown
NCT00507143 2007-07-25
Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan
National Cancer Center, Korea
Phase NA Unknown